In this Healthed lecture, Dr Robert Hungerford discusses the latest evidence-based recommendation to lower LDL-C targets even further in various at-risk groups, as well as the most effective means of reaching those targets in real-world Australian clinical practice. He will also present the value of combination therapy, the value of starting combination early, the role of the newer PCSK9 inhibitors and their current PBS eligibility criteria.
See omnystudio.com/listener for privacy information.
